For the 12 months ending December 31, 2023, the company now expects net revenue of between $433,000,000 443,000,000 Representing a year over year decrease in the range of 1% to 4% as compared to net revenue of $450,900,000 for the year ended December 31, 2022. The 2023 net revenue guidance range assumes net revenue from Advanced Wound Care products of between $406,000,000 $418,000,000 representing a year over year decrease in the range of 1% to 4%. Net revenue from surgical and sports medicine products between $27,000,000 29,000,000 representing a year over year decrease in the range of flat to down 6%. In terms of profitability guidance for 20 The company expects to generate GAAP net income of between $4,000,000 $9,000,000 and adjusted net income of between $11,000,000 17,000,000 We also expect EBITDA between $26,000,000 $37,000,000 and adjusted EBITDA of between $40,000,000 51,000,000 In addition to our formal financial guidance for 2023, we are providing some considerations for modeling purposes. For the fiscal year 2023, we now The midpoint of our total revenue range for 2023 now assumes sales of PuraPly products to decrease approximately 23% year over year and sales of our non PuraPly products will increase approximately 21% year over year.